{"name":"Gao-jun Teng","slug":"gao-jun-teng","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dicycloplatin (TP21)","genericName":"Dicycloplatin (TP21)","slug":"dicycloplatin-tp21","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"}]}],"pipeline":[{"name":"Dicycloplatin (TP21)","genericName":"Dicycloplatin (TP21)","slug":"dicycloplatin-tp21","phase":"phase_3","mechanism":"Dicycloplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to inhibit cancer cell proliferation.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOU1JKa1ZybjB5SVBnNlpEcGRVRlVQcFpwN0dlVGtCcmF3M1NLaUU3SGdtVE8xeXUxOXgzTzd0YUVFZ29KNVZ6bWxFU3NNYUZ5WHdjV3lLclQtbEFSQmE1Y2xBVGg4OGFuUHFTU1BRMmhpaERfaWxTb3hmb0VVQmRaZnBQVUdWMWtwSXY3NHpCV0NHTUl3OTdxVmxsZ0dLQ1F3VmtVVGpZM2o?oc=5","date":"2025-03-25","type":"pipeline","source":"The ASCO Post","summary":"In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers - The ASCO Post","headline":"In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE0za0hyNVdCS0dBZ2lUcGh2TnE3QWhoeDdZRUpLOUJ5a2E0UHpZZ0xRMWRhR0V6WEVFSnBDQl9WLUlQWkRXVzd4eTJHczVIajl0c1BhUmRtaDRUNWNtQldKeUxB?oc=5","date":"2025-02-07","type":"trial","source":"Global Times","summary":"CHANCE 2005/CARES-005 Study Shows PFS Benefit with Combination of Camrelizumab/Rivoceranib and TACE in Unresectable hepatocellular carcinoma (HCC) - Global Times","headline":"CHANCE 2005/CARES-005 Study Shows PFS Benefit with Combination of Camrelizumab/Rivoceranib and TACE in Unresectable hepa","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBPZ3hDTzN0N2Z0Uy01TnFnUHRBd3FRZXRvVkl0TTZHTE9KUm9MbjMyajhzdWVHZW5KczVtNlNYWEQ1clhEdTItTUhESURod21NX1lqRkJNOWxad1JLdnVHM3plU3ZURFlw?oc=5","date":"2025-01-26","type":"pipeline","source":"MedPage Today","summary":"Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer - MedPage Today","headline":"Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}